Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Randy C. Axelrod, MD

Advertisement

Articles by Randy C. Axelrod, MD

The Clinical and Economic Value of Rituximab for the Treatment of Hematologic Malignancies

ByCharles M. Farber, MD, PhD,Randy C. Axelrod, MD
March 15th 2011

Rituximab is a humanized monoclonal antibody that is used for the treatment of a wide variety of B-cell-derived hematologic malignancies

Advertisement

Latest Updated Articles

  • The Clinical and Economic Value of Rituximab for the Treatment of Hematologic Malignancies
    The Clinical and Economic Value of Rituximab for the Treatment of Hematologic Malignancies

    March 15th 2011



Advertisement
Advertisement

Trending on OncLive

1

Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC

2

Oral Administration Afforded by CDK2 Inhibitors May Ease the Price of Admission in Platinum-Resistant Ovarian Cancer

3

Iza-Bren Improves Survival in Unresectable, Locally Advanced or Metastatic TNBC

4

MAIC Shows Improved PFS With Zanubrutinib Over Ibrutinib in Treatment-Naive CLL

5

Zongertinib, Sevabertinib Reshape Treatment Landscape for Patients With HER2-Mutated NSCLC

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us